A Randomized Phase II Study of the Efficacy and Safety of Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing as First-Line Therapy for Metastatic Renal Cell Cancer (Renal EFFECT Trial).
Latest Information Update: 16 Nov 2016
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- Acronyms Renal EFFECT Trial
- Sponsors Pfizer
- 19 Mar 2012 Results published in the Journal of Clinical Oncology.
- 19 Feb 2011 Results presented at the 2011 Genitourinary Cancers Symposium.
- 17 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.